Zimbabwe has turned down a major American health deal valued at $367m (272 million pounds) over five years because of Washington's request for confidential data.
The decision was revealed after a internal memorandum from December was disclosed, revealing that President Emmerson Mnangagwa believed the arrangement was "lopsided".
A government spokesperson has since clarified that the United States was demanding access to genetic material for scientific study and commercial purposes while refused to share the resulting advantages from any future treatments.
"We will now turn to the difficult and regrettable task of winding down our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had provided over $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged more negotiations to reach a agreement suitable to all parties so the country's critical HIV programme can be sustained.
Broader Context
This development comes after a comparable case in neighbouring Kenya, where a court suspended a similar health funding agreement following legal challenges were filed about the security of citizens' health data.
Since returning to office last year, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump claimed its spending was "wasteful" and his administration was pursuing direct bilateral deals to enhance transparency and responsibility.
Based on reports, Sixteen nations in Africa have so far signed similar agreements, representing more than $18.3bn of fresh investment.
Details of the Rejected Agreement
The funds for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration might have yielded extraordinary benefits for Zimbabwean communities, particularly the 1.2 million currently receiving antiretroviral therapy through US-supported programmes," the Ambassador added.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Our nation was requested to surrender its biological resources and data over an extended period, with no equivalent promise of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might be developed from that provided information," his statement read.
"In essence, our country would supply the basic resources for medical research with no certainty that the end products would be available to our population should a new pandemic emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the global health body and its pursuit of one-on-one health agreements were upending systems previously set up via the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with potential pandemics.
"This mechanism is designed to guarantee that when a country contributes its information, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the resources to create them."
These objections regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We are open to ongoing dialogue with our American counterparts on how future co-operation could be structured in a way that respects the sovereignty and interests of both nations."
Medical Community Reaction
Medical experts expressed it understood the government's concerns, but recommended that talks need to persist given that much of the nation's HIV programmes relied on external financing.
"In cases where specific concerns arise, such as those relating to data governance or implementation frameworks, these can often be resolved via technical clarification and mutually agreed protections," it added.
The halted deal emphasises the continuing debate between receiving crucial international aid and safeguarding national sovereignty in an ever more data-driven world.